Glucocorticoids in Leprosy Reversal reaction

1. World Health Organization. Guidelines for the diagnosis, treatment, and prevention of leprosy. New Delhi: World Health Organization; 2018.Search in Google Scholar

2. Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol. 2013;79(6):739-49.10.4103/0378-6323.120719Search in Google Scholar

3. Nery JA da C, Bernardes Filho F, Quintanilha J, Machado AM, Oliveira S de S, Sales AM. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol. 2013;88(5):787-92.10.1590/abd1806-4841.20132004Search in Google Scholar

4. Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM. Epidemiologic characteristics of leprosy reactions [Internet]. Int J Lepr Other Mycobact Dis. 1994 [cited 2018 Dec 11];62(4):559-67. Available from: http://ila.ilsl.br/pdfs/v62n4a09.pdfSearch in Google Scholar

5. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis. 2004;72(2):125-33.10.1489/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2Search in Google Scholar

6. Lockwood DN, Vinayakumar S, Stanley JN, Mcadam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis. 1993;61(1):8-15.Search in Google Scholar

7. Roche PW, Le Master J, Butlin CR. Risk factors for type 1 reactions in leprosy [Internet]. Int J Lepr Other Mycobact Dis. 1997 [cited 2018 Dec 12];65(4):450-5. Available from: http://ila.ilsl.br/pdfs/v65n4a02.pdf.Search in Google Scholar

8. Motta AC, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K, Foss NT. Leprosy reactions: coinfections as a possible risk factor. Clinics (Sao Paulo). 2012;67(10):1145-8.10.6061/clinics/2012(10)05Search in Google Scholar

9. Nery JA da C, Duppre NC, Sales AM, Machado AM, Jardim RM, Illarramendi X. Contribution to diagnosis and management of reactional states: a practical approach. An Bras Dermatol. 2006;81(4):367-75.Search in Google Scholar

10. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014;71(4):795-803.10.1016/j.jaad.2014.03.034Search in Google Scholar

11. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015;28(1):80-94.10.1128/CMR.00079-13Search in Google Scholar

12. Naafs B. Clinical aspects of the reversal reaction. Hansenol Int. 1998;(Special):72-8.Search in Google Scholar

13. Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa P, et al. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. BMC Infect Dis. 2015;15:477.10.1186/s12879-015-1128-0Search in Google Scholar

14. Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, van den Eeden SJ, et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol. 2014;34(2):245-55.10.1007/s10875-013-9979-xSearch in Google Scholar

15. Andersson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, Suneetha L, et al. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun. 2005; 73(6):3725-33.10.1128/IAI.73.6.3725-3733.2005Search in Google Scholar

16. Naafs B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis. 1996;64(4 Suppl):S21-8.Search in Google Scholar

17. Wagenaar IM. Risk factors, early detection and treatment of neuropathy in leprosy. Rotterdam: Erasmus University Rotterdam; 2016.Search in Google Scholar

18. Oliveira MB, Diniz LM. Leprosy among children under 15 years of age: literature review. An Bras Dermatol. 2016;91(2):196-203.10.1590/abd1806-4841.20163661Search in Google Scholar

19. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev. 1991;62(2):113-21.10.5935/0305-7518.199100131870373Search in Google Scholar

20. Selvasekar A, Geetha J, Nisha K, Manimozhi N, Jesudasan K, Rao PS. Childhood leprosy in an endemic area. Lepr Rev. 1999;70(1):21-7.10.5935/0305-7518.1999000610405540Search in Google Scholar

21. Walker SL, Lockwood DNJ. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008;79 (4):372-86.10.47276/lr.79.4.372Search in Google Scholar

22. Raju R, Suneetha S, Jadhav RS, Chaduvula M, Atkinson S, Jain S, et al. Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to and S100-B. Lipids Health Dis. 2014;13:119.10.1186/1476-511X-13-119412450725070345Search in Google Scholar

23. Chhabra N, Bhattacharya SN, Singal A, Ahmed RS, Verma P. Profile of oxidative stress in response to treatment for type 1 leprosy reaction. Lepr Rev. 2015;86(1):80-8.10.47276/lr.86.1.80Search in Google Scholar

24. Morato-Conceicao YT, Alves-Junior ER, Arruda TA, Lopes JC, Fontes CJ. Serum uric acid levels during leprosy reaction episodes. PeerJ. 2016;4:e1799.10.7717/peerj.1799479333026989632Search in Google Scholar

25. Wagenaar I, Post E, Brandsma W, Bowers B, Alam K, Shetty V, et al. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: a randomized controlled trial. PLoS Negl Trop Dis. 2017;11(10):e0005952.10.1371/journal.pntd.0005952564313328976976Search in Google Scholar

26. Lambert SM, Alembo DT, Nigusse SD, Yamuah LK, Walker SL, Lockwood DN. A randomized controlled double blind trial of ciclosporin versus prednisolone in the management of leprosy patients with new type 1 reaction, in Ethiopia. PLoS Negl Trop Dis. 2016;10(4):e0004502.10.1371/journal.pntd.0004502482153527046330Search in Google Scholar

27. Gabriel MTG, Hipolito RH, Chan GP, Senador LR, Lagda D, Gajete FC. Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions : a randomized controlled assessor-blinded clinical trial. Journal of the Philippine Dermatological Society. 2015;24(2):20-9.Search in Google Scholar

28. Durães SM, Salles Sde A, Leite VR, Gazzeta MO. Azathioprine as a steroid sparing agent in leprosy type 2 reactions: report of nine cases. Lepr Rev. 2011;82(3):304-9.10.47276/lr.82.3.304Search in Google Scholar

29. Sahay G, Kar HK, Gupta R. Effect of steroid prophylaxis on nerve function impairment in multi-bacillary leprosy patients on MDT-MB. Indian J Lepr. 2015;87(3):133-43.Search in Google Scholar

30. Smith WC, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls PG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ. 2004;328(7454):1459.10.1136/bmj.38107.645926.AE42851115159285Search in Google Scholar